Kovitz Investment Group Partners
VRCA icon

Kovitz Investment Group Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

Kovitz Investment Group Partners’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,113
Closed -$44.7K – 1402
2025
Q1 		$44.7K Hold
10,113
– – ﹤0.01% 1231
2024
Q4 		$70.8K Hold
10,113
– – ﹤0.01% 1212
2024
Q3 		$147K Buy
10,113
+100
+1% +$4.5K ﹤0.01% 968
2024
Q2 		$730K Buy
10,013
+5,000
+100% +$384K 0.01% 604
2024
Q1 		$297K Hold
5,013
– – ﹤0.01% 585
2023
Q4 		$367K Hold
5,013
– – 0.01% 347
2023
Q3 		$195K Buy
5,013
+1,540
+44% +$78.3K ﹤0.01% 384
2023
Q2 		$200K Hold
3,473
– – ﹤0.01% 398
2023
Q1 		$226K Buy
3,473
+460
+15% +$27.8K ﹤0.01% 396
2022
Q4 		$83K Buy
+3,013
New +$80.4K ﹤0.01% 388

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kovitz Investment Group Partners's VRCA Position: Q2 2025 in Review

Kovitz Investment Group Partners sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 10,113 shares — an estimated $44.7K sold.

Kovitz Investment Group Partners first reported a position in VRCA in Q4 2022 and held it in 10 quarters. The position peaked at $730K in Q2 2024. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

  • Kovitz Investment Group Partners reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 10,113 Verrica Pharmaceuticals shares in Q2 2025, an estimated $44.7K.
  • Kovitz Investment Group Partners first reported a position in Verrica Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Kovitz Investment Group Partners's Verrica Pharmaceuticals position peaked at $730K in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q2 2025, filed 14 Aug 2025.